Vimarsana
Biggest News Aggregation in the World

Jorge Capapey News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jorge Capapey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jorge Capapey Today - Breaking & Trending Today

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release - Vimarsana News

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Press Release

Published: October 7, 2022

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patie

Source: wiredprnews.com
Related Topics:
United StatesUnited KingdomJorge CapapeyKim HollanderHyperoxaluria FoundationGlobal Rare Disease Lead At Alnylam PharmaceuticalsDrug AdministrationAlnylam Pharmaceuticals IncExchange CommissionAlnylam PharmaceuticalsEuropean Medicines AgencyCommittee For Medicinal Products Human UsePrimary Hyperoxaluria TypeLower UrinaryPlasma Oxalate LevelsAdult PatientsPositive EfficacySafety ResultsSevere Renal ImpairmentIncluding ThoseNew Drug ApplicationVice PresidentGlobal Rare Disease LeadMonth SixExecutive Director
FDA approves label expansion of Alnylam's Oxlumo for PH1 - Vimarsana News

FDA approves label expansion of Alnylam's Oxlumo for PH1

Published: October 7, 2022

The US FDA has approved Alnylam Pharmaceuticals’ sNDA for the expanded use of Oxlumo (lumasiran) to treat advanced primary hyperoxaluria type 1 (PH1).

Source: pharmaceutical-business-review.com
Related Topics:
Jorge CapapeyAlnylam Pharmaceuticals Global Rare DiseasePharmaceuticals Global Rare Disease
FDA Expands Label for Alnylam's Oxlumo for Sickest Patients with Rare Disease PH1 - Vimarsana News

FDA Expands Label for Alnylam's Oxlumo for Sickest Patients with Rare Disease PH1

Published: October 7, 2022

The FDA approved Alnylam’s Oxlumo for an expanded indication, rare disease PH1, with the label to include patients with the most severe kidney impairment.

Source: biospace.com
Related Topics:
Jorge CapapeyKim HollanderAlnylam PharmaceuticalsEuropean Medicines AgencyHyperoxaluria FoundationAlnylam Pharmaceutical OxlumoDa Expands Label For Alnylams Oxlumo Sickest Patients With Rare Disease Ph1